| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abnormal preschool Lung Clearance Index (LCI) reflects clinical status and predicts lower spirometry later in childhood in cystic fibrosis
|
Hardaker, K.M.
|
|
2019
|
18 |
5 |
p. 721-727
|
artikel
|
| 2 |
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis
|
Walker, Seth
|
|
2019
|
18 |
5 |
p. 708-713
|
artikel
|
| 3 |
AR-13 reduces antibiotic-resistant bacterial burden in cystic fibrosis phagocytes and improves cystic fibrosis transmembrane conductance regulator function
|
Assani, Kaivon
|
|
2019
|
18 |
5 |
p. 622-629
|
artikel
|
| 4 |
A two-center analysis of hyperpolarized 129Xe lung MRI in stable pediatric cystic fibrosis: Potential as a biomarker for multi-site trials
|
Couch, Marcus J.
|
|
2019
|
18 |
5 |
p. 728-733
|
artikel
|
| 5 |
CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials
|
Bell, Scott C.
|
|
2019
|
18 |
5 |
p. 700-707
|
artikel
|
| 6 |
Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections
|
Banaschewski, Brandon
|
|
2019
|
18 |
5 |
p. 714-720
|
artikel
|
| 7 |
Decreased mRNA and protein stability of W1282X limits response to modulator therapy
|
Aksit, M.A.
|
|
2019
|
18 |
5 |
p. 606-613
|
artikel
|
| 8 |
Differences in the lower airway microbiota of infants with and without cystic fibrosis
|
Frayman, Katherine B.
|
|
2019
|
18 |
5 |
p. 646-652
|
artikel
|
| 9 |
Editorial Board
|
|
|
2019
|
18 |
5 |
p. ii
|
artikel
|
| 10 |
Fair selection of participants in clinical trials: The challenge to push the envelope further
|
Davies, J.C.
|
|
2019
|
18 |
5 |
p. e48-e50
|
artikel
|
| 11 |
Fair subject selection in cystic fibrosis trials
|
Strassle, Camila
|
|
2019
|
18 |
5 |
p. e47
|
artikel
|
| 12 |
GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)
|
Davies, Jane C.
|
|
2019
|
18 |
5 |
p. 693-699
|
artikel
|
| 13 |
Hyperbaric oxygen treatment increases killing of aggregating Pseudomonas aeruginosa isolates from cystic fibrosis patients
|
Møller, Signe Agnete
|
|
2019
|
18 |
5 |
p. 657-664
|
artikel
|
| 14 |
Important steps in the journey to highly effective CFTR modulator access for people with CF
|
VanDevanter, D.R.
|
|
2019
|
18 |
5 |
p. 577-578
|
artikel
|
| 15 |
Inhaled therapies for NTM disease – The way forward?
|
Thomson, Rachel
|
|
2019
|
18 |
5 |
p. 581-583
|
artikel
|
| 16 |
International approaches for delivery of positive newborn bloodspot screening results for CF
|
Chudleigh, J.
|
|
2019
|
18 |
5 |
p. 614-621
|
artikel
|
| 17 |
Interprofessional provider educational needs and preferences regarding the provision of sexual and reproductive health care in cystic fibrosis
|
Kazmerski, Traci M.
|
|
2019
|
18 |
5 |
p. 671-676
|
artikel
|
| 18 |
Lumacaftor-rescued F508del-CFTR has a modified bicarbonate permeability
|
Ferrera, Loretta
|
|
2019
|
18 |
5 |
p. 602-605
|
artikel
|
| 19 |
Measuring recovery in health-related quality of life during and after pulmonary exacerbations in patients with cystic fibrosis
|
Flume, Patrick A.
|
|
2019
|
18 |
5 |
p. 737-742
|
artikel
|
| 20 |
Metagenome – Inferred bacterial replication rates in cystic fibrosis airways
|
Pienkowska, Katarzyna
|
|
2019
|
18 |
5 |
p. 653-656
|
artikel
|
| 21 |
Mild cystic fibrosis in carriers of two nonsense mutations – a case of genetic compensation response?
|
Tümmler, Burkhard
|
|
2019
|
18 |
5 |
p. e51-e52
|
artikel
|
| 22 |
News
|
|
|
2019
|
18 |
5 |
p. 584-586
|
artikel
|
| 23 |
Non-invasive ventilation and clinical outcomes in cystic fibrosis: Findings from the UK CF registry
|
Archangelidi, Olga
|
|
2019
|
18 |
5 |
p. 665-670
|
artikel
|
| 24 |
Physical activity and associations with clinical outcome measures in adults with cystic fibrosis; a systematic review
|
Shelley, James
|
|
2019
|
18 |
5 |
p. 590-601
|
artikel
|
| 25 |
Pseudomonas aeruginosa colonization causes PD-L1 overexpression on monocytes, impairing the adaptive immune response in patients with cystic fibrosis
|
Avendaño-Ortiz, José
|
|
2019
|
18 |
5 |
p. 630-635
|
artikel
|
| 26 |
Speeding up access to new drugs for CF: Considerations for clinical trial design and delivery
|
Davies, Jane C.
|
|
2019
|
18 |
5 |
p. 677-684
|
artikel
|
| 27 |
Systemic levels of anti-PAD4 autoantibodies correlate with airway obstruction in cystic fibrosis
|
Yadav, Ruchi
|
|
2019
|
18 |
5 |
p. 636-645
|
artikel
|
| 28 |
Taskforce recommends coordinated effort to improve clinical research conduct and find highly effective CFTR-directed treatment for rare mutations
|
Solomon, G.M.
|
|
2019
|
18 |
5 |
p. 579-580
|
artikel
|
| 29 |
The impact of cystic fibrosis-related diabetes on health-related quality of life
|
Kwong, Eugenie
|
|
2019
|
18 |
5 |
p. 734-736
|
artikel
|
| 30 |
Theranostics by testing CFTR modulators in patient-derived materials: The current status and a proposal for subjects with rare CFTR mutations
|
Amaral, Margarida D.
|
|
2019
|
18 |
5 |
p. 685-692
|
artikel
|
| 31 |
Total pancreatectomy with islet autotransplantation in a pancreatic-sufficient cystic fibrosis patient
|
St Onge, Ina
|
|
2019
|
18 |
5 |
p. e53-e55
|
artikel
|
| 32 |
Transcript from Stuart Elborn's address at the ECFC award in June 2019
|
|
|
2019
|
18 |
5 |
p. 587-589
|
artikel
|
| 33 |
Who and why; sharing our experiences of developing a standard operating procedure (SOP) to allocate screening slots for highly competitive cystic fibrosis trials
|
Dobra, Rebecca
|
|
2019
|
18 |
5 |
p. e45-e46
|
artikel
|
Tijdschrift beschrijving